EMA Authorised: Neofordex (dexamethasone) — THERAVIA

View source ↗

Summary

European Medicines Agency authorised Neofordex (dexamethasone) for therapeutic use, with THERAVIA as the marketing authorization holder, in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Neofordex (dexamethasone)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: THERAVIA. Decision date: 09/07/2026